High Rabbit-Antihuman Thymocyte Globulin Levels Are Associated with Low Likelihood of Graft-vs-Host Disease and High Likelihood of Posttransplant Lymphoproliferative Disorder

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 7, 2010, Pages 915-926

  Podgorny, Peter J ^a   Ugarte Torres, Alejandra ^a   Liu, Yiping ^a   Williamson, Tyler S ^a   Russell, James A ^a   Storek, Jan ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Antythymocyte globulin (ATG); Graft versus host disease (GVHD); Posttransplant lymphoproliferative disorder (PTDL)

Indexed keywords

ACICLOVIR; ATG F; BUSULFAN; COTRIMOXAZOLE; CYCLOSPORIN; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CANCER MORTALITY; CANCER RELAPSE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PNEUMOCYSTOSIS; SECOND CANCER; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTILYMPHOCYTE SERUM; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; RABBITS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TISSUE AND ORGAN HARVESTING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953617062     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.02.027     Document Type: Article

References (46)

1. Frassoni F. Anti-T-cell globulin: an essential ingredient for haematopoietic cell transplantation?. Lancet Oncol 2009, 10:839.
2. Sormani M.P., Ibatici A., Dominietto A., et al. Graft-versus-host disease prophylaxis with antithymocyte globulin: which is more important, dose or timing?. Bone Marrow Transplant 2007, 39:S25.
3. Kim H.J., Min W.S., Cho B.S., et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2009, 15:704-717.
4. Chen X.H., Zhang C., Zhang X., et al. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2009, 15:266-273.
5. Bredeson C.N., Zhang M.J., Agovi M.A., et al. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:993-1003.
6. Ayuk F., Diyachenko G., Zabelina T., et al. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors. Exp Hematol 2008, 36:1047-1054.
7. Ayuk F., Diyachenko G., Zabelina T., et al. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:913-919.
8. Russell J.A., Turner A.R., Larratt L., et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant 2007, 13:299-306.
9. Deeg H.J., Storer B.E., Boeckh M., et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006, 12:573-584.
10. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
11. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 98:2942-2947.
12. Champlin R.E., Perez W.S., Passweg J.R., et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007, 109:4582-4585.
13. Van Lint M.T., Milone G., Leotta S., et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006, 107:4177-4181.
14. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007, 21:1387-1394.
15. LaCorcia G., Swistak M., Lawendowski C., et al. Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion. Transplantation 2009, 87:966-974.
16. Eiermann T.H., Lambrecht P., Zander A.R. Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. Bone Marrow Transplant 1999, 23:779-781.
17. Haidinger M., Geyeregger R., Poglitsch M., et al. Antithymocyte globulin impairs T-cell/antigen-presenting cell interaction: disruption of immunological synapse and conjugate formation. Transplantation 2007, 84:117-121.
18. Call S.K., Kasow K.A., Barfield R., et al. Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant 2009, 15:274-278.
19. Zhang X.H., Huang X.J., Liu K.Y., Xu L.P., Liu D.H., Lu D.P. [Pharmacokinetics of antithymocyte globulin in recipients under-going HLA partially matched hematopoietic stem cell transplantation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007, 15:152-155.
20. Remberger M., Sundberg B. Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica 2005, 90:931-938.
21. Seidel M.G., Fritsch G., Matthes-Martin S., et al. Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2005, 27:532-536.
22. Kakhniashvili I., Filicko J., Kraft W.K., Flomenberg N. Heterogeneous clearance of antithymocyte globulin after CD34+-selected allogeneic hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2005, 11:609-618.
23. Bunn D., Lea C.K., Bevan D.J., Higgins R.M., Hendry B.M. The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol 1996, 45:29-32.
24. Tchervenkov J., Flemming C., Guttmann R.D., desGachons G. Use of thymoglobulin induction therapy in the prevention of acute graft rejection episodes following liver transplantation. Transplant Proc 1997, 29:S13-S15.
25. Grullich C., Ziegler C., Finke J. Rabbit anti T-lymphocyte globulin induces apoptosis in peripheral blood mononuclear cell compartments and leukemia cells, while hematopoetic stem cells are apoptosis resistant. Biol Blood Marrow Transplant 2009, 15:173-182.
26. Schattenberg A., van der Meer A., Preijers F., et al. Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors. Bone Marrow Transplant 2004, 33:1115-1121.
27. Russell J.A., Savoie M.L., Balogh A., et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 2007, 13:814-821.
28. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
29. Lowe T., Bhatia S., Somlo G. Second malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007, 13:1121-1134.
30. Landgren O., Gilbert E.S., Rizzo J.D., et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009, 113:4992-5001.
31. Remberger M., Sundberg B. Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. Biol Blood Marrow Transplant 2009, 15:996-999.
32. Basara N., Baurmann H., Kolbe K., et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 2005, 35:1011-1018.
33. Remberger M., Svahn B.M., Mattsson J., Ringden O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004, 78:122-127.
34. Meijer E., Cornelissen J.J. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr Opin Hematol 2008, 15:576-585.
35. Omar H., Hagglund H., Gustafsson-Jernberg A., et al. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transpl Infect Dis 2009, 11:393-399.
36. van Esser J.W., Niesters H.G., van der Holt B., et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002, 99:4364-4369.
37. Swinnen L.J. Immune-cell treatment of Epstein-Barr-virus-associated lymphoproliferative disorders. Best Pract Res Clin Haematol 2006, 19:839-847.
38. Gottschalk S., Rooney C.M., Heslop H.E. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005, 56:29-44.
39. Wagner H.J., Cheng Y.C., Huls M.H., et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004, 103:3979-3981.
40. Ruzek M.C., Neff K.S., Luong M., et al. In vivo characterization of rabbit anti-mouse thymocyte globulin: a surrogate for rabbit anti-human thymocyte globulin. Transplantation 2009, 88:170-179.
41. Tabrizi M.A., Tseng C.M., Roskos L.K. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006, 11:81-88.
42. Regan J.F., Lyonnais C., Campbell K., Smith L.V., Buelow R. Total and active thymoglobulin levels: effects of dose and sensitization on serum concentrations. Transpl Immunol 2001, 9:29-36.
43. Atkinson K., Champlin R., Ritz J., Fibbe W.E., Ljungman P., Brenner M.K. Clinical Bone Marrow and Blood Stem Cell Transplantation 2004, Cambridge University Press, Cambridge.
44. Chames P., Van Regenmortel M., Weiss E., Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009, 157:220-233.
45. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
46. Bacigalupo A., Lamparelli T., Milone G., et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants. Bone Marrow Transplant 2010, 45:385-391.